OA
Therapeutic Areas
Corvus Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Soquelitinib (CPI-818) | Relapsed/Refractory T Cell Lymphomas (TCL) | Phase 1 |
| Ciforadenant (CPI-444) | Cancer | Phase 1/2 |
| Mupadolimab (CPI-006) | Non-Small Cell Lung Cancer (NSCLC) | Phase 1/2 |
Leadership Team at Corvus Pharmaceuticals
RA
Richard A. Miller, M.D.
President, CEO, and Co-Founder
LL
Leiv Lea
Chief Financial Officer
JA
Jeffrey Arcara
Chief Business Officer
WB
William Ben Jones, Ph.D.
Senior Vice President, Pharmaceutical Development
GL
Gabriel Luciano
Vice President, Clinical Operations